SM
MDGL icon

SG3 Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

SG3 Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,000
Closed -$290K – 107
2022
Q4 		$290K Buy
+1,000
New +$97.8K 0.04% 145

Other funds holding MDGL

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

SG3 Management's MDGL Position: Q1 2023 in Review

SG3 Management sold out of Madrigal Pharmaceuticals (MDGL) in Q1 2023, closing a stake of 3,100 shares — an estimated $900K sold.

SG3 Management first reported a position in MDGL in Q4 2022 and held it in 1 quarter. The position peaked at $900K in Q4 2022. 223 funds tracked by Wall St. Rank hold MDGL as of Q1 2023.

  • SG3 Management reported no remaining Madrigal Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • SG3 Management sold 3,100 Madrigal Pharmaceuticals shares in Q1 2023, an estimated $900K.
  • SG3 Management first reported a position in Madrigal Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • SG3 Management's Madrigal Pharmaceuticals position peaked at $900K in Q4 2022.
  • 223 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2023.

Based on SG3 Management's 13F filing for Q1 2023, filed 15 May 2023.